Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France.
Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France.
Rev Neurol (Paris). 2021 Dec;177(10):1237-1240. doi: 10.1016/j.neurol.2021.05.001. Epub 2021 Jun 16.
To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection.
We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups.
In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58-28.6], 16.5 [16.3-48.5], 1116 [434-1747] and 1272 [658-1886], respectively, P<0.001). Similar results were found for MS patients after COVID-19.
Patients with MS and treated with S1PR modulators or anti-CD20 mAb had a reduced humoral response after COVID-19 vaccine.
根据疾病修正治疗（DMT）分析 COVID-19 疫苗接种后多发性硬化症（MS）患者的体液反应，并与 COVID-19 感染后的体液反应进行比较。
我们纳入了 28 名在法国斯特拉斯堡 MS 中心随访的 MS 患者，这些患者在 2021 年 1 月至 4 月期间有 COVID-19 疫苗接种（辉瑞-生物科技或 Moderna ARNm）后的血清学结果，以及 61 名有 COVID-19 血清学结果的 MS 患者（COVID-19 组）。主要终点是根据 DMT（抗 CD20 mAb、鞘氨醇 1-磷酸受体[S1PR]调节剂和其他治疗）和 COVID-19 疫苗或 COVID-19 组的 IgG 指数。
在接种疫苗的 MS 患者中，与接受其他或无 DMT 的患者相比，接受抗 CD20 mAb 和 S1PR 调节剂治疗的患者的 IgG 指数较低（4.80 [1.58-28.6]、16.5 [16.3-48.5]、1116 [434-1747] 和 1272 [658-1886]，P<0.001）。COVID-19 后 MS 患者也有类似的结果。
接受 S1PR 调节剂或抗 CD20 mAb 治疗的 MS 患者 COVID-19 疫苗接种后的体液反应降低。
